कोशिश गोल्ड - मुक्त

Strategic HR for Today's Biotech M&As

Bio Spectrum

|

January 2017

The pharmaceutical and bio-technology sectors have been witnessing a strong trend of consolidation through mergers and acquisitions (M&A) over the last few years.

- Amitava Saha

Strategic HR for Today's Biotech M&As

Globally, 166 M&A deals were announced in the pharmaceutical and biotechnology sectors in 2015, up from 137 in 2014, according to The Pharma Letter. Moreover, the number of deals exceeding USD1 billion rose to 30 in 2015 versus 26 in 2014 and 20 in 2013.

Not only are the number of deals increasing, their size is going up too. The average potential deal value in the biotech sector increased to USD320 million in 2015 from USD309 million in 2014, according to a report by E&Y. In 2015, 17 of the alliances in this sector had a total potential value greater than USD1 billion versus 12 in 2014 and only five in 2013.

The reasons behind the rise in the intensity of deal making are not hard to seek. A drop in earnings due to patent expiries on blockbuster drugs, declining R&D productivity and rising pricing pressure are leading to heightened M&A activity. Moreover, US drugmakers are looking at the M&A route to cash in on the benefits of low corporate tax rates in other countries. In the biotech sector, M&As are being driven by the desire of larger biopharma players to secure access to innovative technology platforms.

Why HR is key to successful M&As

Given the mega size of these transactions, there’s more pressure than ever on company managements to ensure that M&As are consummated with as less friction as possible so that the combined entity works as a single unified team to realize the potential benefits of the merger. It is here that the Human Resources (HR) function has a key role to play. HR has the greatest impact in the process of integrating two sets of employees and their daily work processes. One of the potent ways in which HR can ensure a smooth transition to a unified entity post a M&A deal is by focusing on defining a set of desirable cultural attributes and then getting employees to quickly adopt these attributes in their daily behaviour.

Bio Spectrum से और कहानियाँ

Bio Spectrum

Bio Spectrum

Molbio announces collaboration with UE LifeSciences to expand iBreastExam globally

Molbio Diagnostics, a Goa-based point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies, and UE LifeSciences, a Philadelphia-based innovator engaged in the business of developing and manufacturing health technology solutions, with a primary focus on enabling early cancer detection technologies, have announced an exclusive collaboration, seeking to make early breast cancer detection accessible to millions of women in over 50 countries across the developing world.

time to read

1 min

November 2025

Bio Spectrum

Bio Spectrum

CRO Reforms: Tilting Scale towards Accelerated Growth & Transparency

India's clinical research ecosystem is undergoing a major transformation, driven by a wave of regulatory reforms and rapid market expansion.

time to read

10 mins

November 2025

Bio Spectrum

When Spectra Speak: Letting AI Read the Fine Print of Biologics

Biologic characterisation has historically relied heavily on spectroscopy, which transforms chemical complexity into comprehensible fingerprints. Through the careful use of AI, supported by strict data procedures and scientific supervision, these fingerprints may be read more quickly & thoroughly.

time to read

5 mins

November 2025

Bio Spectrum

Working on our supply chain to set benchmarks in quality and further enhance India's position as a trusted clinical research supplier on a global scale

Abdos Lifesciences, which is committed to enabling science to thrive by delivering precision-engineered, high-performance laboratory consumables and instruments that meet the highest global standards, manufactures over 400 products across 12+ categories in automated cleanroom environments certified under ISO and CE-IVDR standards, ensuring sterility, traceability, and consistency crucial for decentralised and global clinical trials. Each product is barcoded, tamper-proof, and supported by easily accessible documentation such as Certificates of Analysis (COA), Technical Data Sheets (TDS). With a presence in more than 90 countries, Abdos Lifesciences ensures researchers worldwide receive reliable products and dedicated support, empowering science to advance seamlessly across borders and timelines. In an interview with BioSpectrum India Shrey Agarwal, CEO & Director, Abdos Lifesciences spoke to many issues including how the company is ensuring compliance with evolving global standards for products used in regulated clinical environments. Edited excerpts;

time to read

4 mins

November 2025

Bio Spectrum

Gene Solutions and AMPATH launch advanced genomics laboratory in Hyderabad

Gene Solutions, a leading genetic testing innovator in Asia, has partnered with AMPATH (American Institute of Pathology and Laboratory Sciences), a trusted provider of high-quality diagnostic services in India, to open a new advanced genomics laboratory in Hyderabad.

time to read

1 min

November 2025

Bio Spectrum

Patient Consent - How is it different under medical ethics and data protection?

In the ethical and legal framework of medicine and law, consent has always existed. Within healthcare, it signifies the individual's right to be informed and to choose. However, in the digital era, consent assumes a broader function; it becomes the foundation for lawful processing of personal data. For the pharma and clinical-research sectors, this distinction carries significant implications. The Digital Personal Data Protection Act, 2023 (DPDPA), has redefined how personal and health-related data must be managed. This article explores why consent under data-protection law differs from medical consent, drawing lessons from the irregularities uncovered in the Ahmedabad clinical trials, and outlines the emerging compliance responsibilities under the DPDPA.

time to read

3 mins

November 2025

Bio Spectrum

Bio Spectrum

We aim to make bio-based industries a key pillar of the state's GSDP by 2030: Kerala CM

Kerala recently set the spotlight on its growing life sciences ecosystem with Bio Connect 3.0 – International Life Sciences Conclave & Expo, held on October 9 & 10, 2025, in Thiruvananthapuram.

time to read

3 mins

November 2025

Bio Spectrum

Bio Spectrum

DBT inks pact with Uttar Pradesh to boost biotech, pharma and medtech innovation

An official Memorandum of Understanding (MoU) has been signed between the Department of Biotechnology (DBT), Government of India and the Government of Uttar Pradesh.

time to read

1 min

November 2025

Bio Spectrum

Bio Spectrum

Abbott launches world's first dual-chamber leadless pacemaker system in India

Abbott, a global healthcare company, has announced the launch of AVEIR dual chamber (DR) leadless pacemaker system - the first of its kind in the world.

time to read

1 min

November 2025

Bio Spectrum

Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr

Delhi-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).

time to read

1 min

November 2025

Translate

Share

-
+

Change font size